Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines

Oncoimmunology. 2013 Feb 1;2(2):e23040. doi: 10.4161/onci.23040.


In vivo dendritic-cell targeting constitutes a promising strategy for anticancer vaccination. Here, we discuss the usage of multivalent DC-SIGN-targeting glycan platforms that allow for the efficient routing of antigens to the endo-lysosomal pathway as well as to a yet uncharacterized cross-presentation mechanism inducing CD4+ and CD8+ T-cell responses.

Keywords: DC-SIGN; cell surface molecules; dendritic cells; glycans; human; rodent.